Me likey, from 10k:
In addition, research conducted by ChemDiv on Regen’s behalf has identified a compound that activate NR2F6 which appears to be effective in treating autoimmune diseases with virtually no toxicity.
((outstanding common actually DECREASED))... 139,704,157 issued and outstanding as of September 30, 2017 and 139,712,605 shares issued and outstanding September 30, 2016...((however)) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 141,426,429 ((Sept 2017 vs))127,840,131 ((Sept 2016))((I dont have time to analyze))
((Outstanding Series A preferred shares only went up by about 1.7mm shares over the past year.))
((As a BMSN holder, me likey))As of September 30, 2017 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090.((BUT, i think some were converted to Preferred somewhere along the way, because now:))Series A Preferred Includes 2,907,666 shares of the Company beneficially owned by Bio-Matrix Scientific Group Inc.((and))Includes 30,000 ((Series AA Prefered)) shares of the Company beneficially owned by Bio-Matrix Scientific Group Inc.((BMSN still owns 29mm Regen))
((lot of patents....valuable or not remains to be seen))
The following is a list of patents to which a license has been granted to the Company pursuant to the Benitec Agreement:
US 8,067,383 (was 10/346,853)
US 11/218,999
US 7754697
US 8048670 (was 10/759,841)
US 8053419 (was 10/821,726)
US 90/007,247
CONTROL OF GENE EXPRESSION WO99/49029
Graham, Rice, Waterhouse, Wang AU 743316
AU 2005211538
AU 2005209648
AU 2008249157
BR PI9908967.0
BR PI9917642.4
CA 2323726
CN 200510083325.1
CN 200910206175
CZ 295108
EP 1555317 (formerly patent application no. 04015041.9)
EP 1624060 (formerly patent application no.05013010.3
EP 07008204.5
EP 10183258.2
UK GB 2353282
HK 1035742
HG PO5000631
HG PO101225
IN 3901/DELNP/2005
IN 2000/00169/DE
JP 2000-537990
JP 2005-223953
JP 2007-302237
JP 2009-161847
KR
10-2010-7006892
Divisional of 7010419/00
MX PA/a/2000/008631
MX PA/a/2005/006838?
NZ 506648
NZ 547283
PL P-377017
SG 75542
SG 200205122.5
SG 141233
SL 287538
ZA 2000/4507
SG 141233
Patent Name Inventors Country Application/ Grant No
METHODS AND MEANS FOR OBTAINING MODIFIED PHENOTYPES Waterhouse, Wang, Graham AU 29514/99 (760041)
AU 2007201023
CA 2325344
CN ZL99805925.0 (CN1202246-C)
EP 99910592.7 (EP1068311)
JP 2000-543598
NZ 507093
US 09/287632
US 11/364183
US 11/841737 US20080104732.
Title Inventors Country Number
GENETIC SILENCING Graham, Rice, Murphy, Reed JP 2001-569332
BR PI0109269-3
UK GB2377221
SG 91678
ZA 2002/07428
DOUBLE-STRANDED NUCLEIC ACID
(LONG HAIR PIN)
Graham, Rice, Roelvink, Suhy, Kolkykhalov, Harrison, Reed. AU 2004243347
NZ 543815
EP 04735856.9
CA 2527907
JP 2006-508084
ZA 2005/09813
SG 200507474-5
IL 172191
US 12/914893 Continuation of 10/861191
RNAi EXPRESSION CONSTRUCTS (single promoter)
Roelvink, Suhy, Kolykhalov, Couto US 7,803,611
US 11/883645
CN 200680010811.3
HK 08112495.7
EP 09015950.0
CA 2596711
AU 2006210443
IL 185315
NZ 560936
The Company has also been assigned the following patents.
US Patent #8389708
METHOD OF CANCER TREATMENT USING SIRNA SILENCING
US Patent #9091696
MODULATION OF NR2F6 AND METHODS AND USES THEREOF
US Patent #8263571
Gene silencing of the brother of the regulator of imprinted sites (BORIS)
***********************************************
((informational))
The Company’s authorized capital stock consists of the following:
Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 146,181,009 shares issued and outstanding as of December 21, 2017.
Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of December 21, 2017 and 300,000,000 is designated Series A Preferred Stock of which 136,966,697 shares are outstanding as of December 21, 2017 and 300,000,000 is designated Series M Preferred Stock of which 38,000,000 shares are outstanding as of December 21, 2017.
Regen still owns 8,000,000 Entest shares, and 185k of convertible preferred share in Entest
****************************************************
((Me no-likey))
Living off of selling shares...not sure what the alternative is at this point
High salaries accruing
Still not forthcoming about many things it seems.
ALL IMO...107 page 10K. Just browsed it.
RGBP
